GC203 TIL / Gencells Therapeutics - LARVOL DELTA

KUNLUN-001: A Study of GC203 TIL in Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Shanghai Juncell Therapeutics | Trial primary completion date: Nov 2025 ➔ Nov 2026

Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Hormone Receptor Positive Breast Cancer • Lung Cancer • Oncology • Solid Tumor

A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital) (clinicaltrials.gov) - P1 | N=26 | Completed | Sponsor: Shanghai Juncell Therapeutics | Recruiting ➔ Completed | N=50 ➔ 26

Enrollment change • Trial completion • Gynecologic Cancers

GC203 for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Shanghai Juncell Therapeutics

New P1 trial • Solid Tumor

A Study of Gene-edited GC203 TIL on the Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Shanghai Juncell Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

A Study of Gene-edited GC203 TIL on the Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Shanghai Juncell Therapeutics

New P1 trial • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

TIL-JC-DG-001: A Study on TIL for the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Shanghai Juncell Therapeutics

Metastases • New P1 trial • Oncology • Solid Tumor

Study on TIL Engineered With Membrane-Binding Cytokine for the Treatment of Advanced Gynecologic Tumors (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Shanghai Juncell Therapeutics | Trial primary completion date: Mar 2024 ➔ Mar 2025

Metastases • Trial primary completion date • Gynecologic Cancers • Oncology

KUNLUN-001: Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Shanghai Juncell Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Gynecologic Cancers • Lung Cancer • Oncology • Solid Tumor

Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024 (PRNewswire) - P1 | N=50 | NCT05468307 | Sponsor: Shanghai Juncell Therapeutics | "Shanghai Juncell Therapeutics Co., Ltd...announced latest clinical research results on GC203 (a novel non-viral vector gene-modified TIL therapy engineered with membrane-bound IL-7). These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place on May 31 - June 4, 2024....GC203 showed promising results in patients with recurrent or metastatic ovarian cancer....No grade 5 event occurred. By the cutoff date of 01/2024, the investigator-assessed Objective Response Rate (ORR) was 33.3% (95% CI: 16.3 - 56.3), including 11.1% Complete Response (CR). The Disease Control Rate (DCR) was 83.3% (95% CI, 60.8 - 94.2). And the 12-month Overall Survival (OS) rate was 68.8% (95% CI: 49.3 - 95.9). The median OS was not mature as data cut-off."

P1 data • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

KUNLUN-001: Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Shanghai Juncell Therapeutics

Metastases • New P1 trial • Breast Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Gynecologic Cancers • Lung Cancer • Oncology • Solid Tumor

Study on TIL Engineered With Membrane-Binding Cytokine for the Treatment of Advanced Gynecologic Tumors (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Shanghai Juncell Therapeutics

New P1 trial • Gynecologic Cancers • Oncology • Solid Tumor